A market research report by HTF MI Research evaluates the global bispecific antibodies for cancer market from 2020 to 2031, projecting a compound annual growth rate (CAGR) of 22.4%. The market is valued at USD 6.547 billion currently and is segmented by application, type, cancer type, and geography. Key players include Amgen, Genmab, Bristol-Myers Squibb, Regeneron, Novartis, Sanofi, Pfizer, GSK, AbbVie, Merck & Co., Eli Lilly, Janssen Biotech, Roche, BioNTech, Sutro Biopharma, Innate Pharma, Zymeworks, and Xencor. Market drivers include rising cancer prevalence, technological advances, and increased investments. Opportunities lie in combination therapies, personalized medicine, and expanded delivery methods. The report analyzes regional consumption, revenue, and growth, with North America and Europe leading, and includes competitive assessments via SWOT and Porter’s Five Forces analysis.

In 2024, top executives at leading healthcare companies received substantial compensation, reflecting the industry's profitability despite underperformance in shareholder expectations. While some CEOs, like Karen Lynch of CVS Health, left their positions with large payouts, others, including BioNTech’s Şahin and DaVita’s Rodriguez, received the highest pay packages, with compensation largely tied to tenure and company stability.

CureVac, a German biotechnology company focused on mRNA-based therapies, announced its financial results for the second quarter and first half of 2025. The company reported a significant decrease in revenue due to restructuring of its partnership with GSK and reduced sales to CRISPR Therapeutics. Despite lower revenues, operating losses declined year-over-year as a result of cost reductions from workforce restructuring and a shift in expenses from cost of sales to research and development. CureVac received clearance from the European Medicines Agency (EMA) for its cancer immunotherapy candidate CVHNLC targeting squamous non-small cell lung cancer (sqNSCLC), and its Phase 1 glioblastoma program (CVGBM) remains on track for data evaluation in H2 2025. The company also entered into a definitive purchase agreement with BioNTech to acquire all shares of CureVac, uniting two leading German mRNA companies to advance global mRNA-based treatments. Additionally, CureVac and GSK will receive $740 million in payments and single-digit royalties from U.S. vaccine sales, with an additional $50 million from GSK for monetizing U.S. product royalties. The company maintains a strong cash position of €392.7 million as of June 30, 2025, with an expected cash runway into 2028.

Cantor Fitzgerald has lowered its price target for Bristol-Myers Squibb Co. (BMY) from $55.00 to $45.00, maintaining a Neutral rating. The firm cites mixed quality in the company's top-line performance, attributing growth to legacy products and foreign exchange effects. It highlights ongoing clinical setbacks and uncertainty about long-term growth, with the upcoming Cobenfy ADEPT-2 trial results as a key catalyst. The firm sees potential upside to $52-54 or downside to $38-40. Meanwhile, BioNTech SE reported a 100% year-over-year revenue increase to €260.8 million, exceeding analyst expectations, but posted a net loss of €386.6 million. Revenue growth was partially driven by a deal with Bristol-Myers Squibb.

Pfizer Inc. and BioNTech SE have completed a Phase 1/2, randomized, observer-blinded clinical study evaluating the safety, tolerability, and immunogenicity of combined influenza and COVID-19 vaccines in healthy adults. The study tested various vaccine combinations, including the Pfizer-BioNTech COVID-19 vaccine, investigational influenza vaccines, licensed influenza vaccines, and a combined influenza-COVID-19 product, administered alone or with placebos. The trial was quadruple-masked and conducted from November 11, 2024, to August 12, 2025. The primary objective was to assess the vaccines' ability to prevent illness. Completion of the study may influence future vaccine offerings and positively impact stock performance, with results available via the ClinicalTrials portal.